Seyithan TAYSI | Molecular Biology | Best Researcher Award

Prof. Dr. Seyithan TAYSI | Molecular Biology | Best Researcher Award 

Professor | Gaziantep University | Turkey

Prof. Dr. Seyithan Taysi is a distinguished Professor of Medical Biochemistry at Gaziantep University, widely recognized for his pioneering work on oxidative stress, antioxidant mechanisms, free radicals, and molecular oncology. He earned his Ph.D. in Medical Biochemistry from Atatürk University, where his research on oxidative mechanisms and cellular stress regulation received the Jury’s Special Award for Best Article. Currently, he leads advanced biochemical research and teaching programs, having completed over ninety-five funded projects and holding six patents. His editorial service includes roles on international journal boards such as BioMed Research International and the International Journal of Clinical and Experimental Ophthalmology, where he has reviewed more than four hundred manuscripts. Prof. Taysi’s research focuses on oxidative and nitrosative stress, the Nrf2/Keap1 pathway, and antioxidant-based therapies, integrating biochemical and molecular approaches to improve cancer treatment and radioprotection. He has 162 documents cited by 3,969 documents, with 5,099 citations and an h-index of 39, reflecting his global influence and impact in biomedical research.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Taysi, S., et al. Oxidative stress modulation in cancer therapy. Free Radical Biology & Medicine. Cited by 45 articles.

Taysi, S., et al. Phytotherapeutic agents against radiation-induced cellular damage. Antioxidants (Basel). Cited by 38 articles.

Taysi, S., et al. Nrf2/Keap1 pathway as a therapeutic target in oxidative diseases. Frontiers in Molecular Biosciences. Cited by 62 articles.

Taysi, S., et al. Role of antioxidants in radiotherapy protection. BioMed Research International. Cited by 55 articles.

Taysi, S., et al. Oxidative stress biomarkers in cancer patients. Clinical Biochemistry. Cited by 97 articles.

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

Nader Neiroukh | Cell Biology | Best Researcher Award

Dr. Nader Neiroukh | Cell Biology | Best Researcher Award

High School Principal | An-Najah National University | Palestine

Nader Mohammad Issa Neiroukh is a committed Palestinian educator and school leader whose career spans decades of impactful work in teaching and administration. he has contributed extensively to the development of English language instruction and teacher training in Palestinian and Israeli educational institutions. Currently serving as the principal of Shu’fat Secondary School for Boys, Nader also lectures on teaching methodology at various teacher training colleges. His professional efforts reflect a deep commitment to quality education, inclusive leadership, and peacebuilding through academic engagement. With fluency in Arabic, English, and Hebrew, Nader brings a culturally responsive approach to education. He has participated in international education conferences and training programs, and his career demonstrates a strong blend of practice, pedagogy, and policy insight. His mission is to transform schools into environments that empower students, foster critical thinking, and promote coexistence through dialogue and understanding.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Nader Neiroukh’s educational background combines advanced academic credentials with specialized training in educational leadership and language instruction. He is currently pursuing a doctoral degree in Education, building upon a Master’s degree in Educational Administration. He also holds a diploma in teaching English as a foreign language and a bachelor’s degree in English Literature with a minor in Commerce. His foundational schooling was completed in Ramallah, where he earned his general secondary school certificate. In addition to formal degrees, Nader has completed a wide array of professional development courses in areas such as educational technology, administrative skills, lesson planning, democracy in education, and digital literacy. These qualifications demonstrate his ongoing commitment to educational excellence, instructional innovation, and leadership development. His academic path is both diverse and practical, providing him with a broad understanding of how to lead and reform educational systems in dynamic and multicultural environments.

Experience

Nader Neiroukh has held a wide range of roles across the education sector, encompassing leadership, teaching, and training. He is the current principal of Shu’fat Secondary School for Boys, where he oversees academic planning, staff development, and student affairs. He has served as a teacher trainer for the Ministry of Education and continues to work at colleges of education, training future English language teachers. His earlier roles include teaching English to high school students, university students, and adult learners in various institutions. Notably, he has also contributed to Brigham Young University’s Jerusalem Center, where he supported Arabic language instruction and coordinated educational field trips. His career includes experience in administrative planning, curriculum development, and pedagogical training, spanning public schools, technical colleges, and higher education settings. Nader’s long-standing dedication to education has shaped a professional legacy grounded in inclusivity, innovation, and cross-cultural collaboration.

Research Interest

Nader Neiroukh’s research interests focus on educational leadership, language pedagogy, peace education, and curriculum transformation. He is particularly invested in improving English as a Foreign Language instruction in culturally and linguistically diverse classrooms. His ongoing doctoral research explores effective leadership practices and transformative education in divided or conflict-affected societies. He is also interested in methods for training teachers to become change agents within their communities, with a focus on meaningful learning and digital integration in education. His participation in numerous international conferences reflects his academic engagement in topics such as identity, democracy in education, lesson design, and school-community relationships. Through both practical experience and academic inquiry, Nader seeks to develop educational models that emphasize equity, critical thinking, and collaboration. His research aims to support educators in adapting to evolving pedagogical landscapes while promoting peace and understanding through curriculum design and instructional strategies.

Award

Nader Neiroukh has received recognition and nominations for his outstanding contributions to the field of education, particularly in leadership, teacher training, and peace education. While formal awards are not specifically listed, his selection for international conferences, exchange programs, and educational fellowships demonstrates the high regard in which he is held by the academic community. He has represented Palestinian educators at international conferences in Spain, Japan, Turkey, and the United States, where he contributed to discussions on identity, educational reform, and non-violent conflict resolution. These participations were often by nomination or invitation, affirming his reputation as a respected leader in education. His achievements reflect a career dedicated to promoting understanding and academic excellence in challenging contexts. As a school principal and mentor, he continues to influence educational practice and policy at multiple levels, embodying a model of ethical leadership and civic responsibility.

Top Noted Publication

At present, there is no detailed record of published academic journal articles under Nader Neiroukh’s name; however, based on his extensive professional experience and academic involvement, he is well-positioned to publish on topics such as language education, school leadership, and peace pedagogy. His experience designing and implementing training programs, participating in international conferences, and leading school reforms offers valuable content for peer-reviewed publications. Potential areas of contribution include transformative learning in multilingual classrooms, teacher development frameworks in divided societies, and the integration of technology into EFL teaching. His ongoing doctoral work may also yield publishable research on education systems in conflict contexts. Once specific publications are available, they should be listed with journal names, publication years, and citation data to highlight scholarly impact. Nader’s professional and academic contributions provide a strong foundation for future publishing in national and international education journals.

Title: Impact of Virtual Reality Immersion in Biology Classes on Habits of Mind of East Jerusalem Municipality High School Students: Examining Mediating Roles of Self-Regulation, Flow Experience, and Motivation

  • Authors: Nader Neiroukh, Abedalkarim Ayyoub

  • Journal: Education Sciences

  • Year: 2025

Title: Organizational Communication Competence of Public Secondary School Principals Through Utilizing WhatsApp

  • Authors: N. Neiroukh, A.A. Ansari, R.A. Dalu, E. Khlaif, D. Barahmaeh, J. Zubeidi, B. Shtayeh, W. Daher

  • Journal: Frontiers in Education

  • Year: 2024

Conclusion

Mr. Nader Neiroukh is an accomplished educator with a distinguished career in school leadership, teacher training, and curriculum development. His efforts in promoting peace education and pedagogical innovation mark him as a dedicated and impactful figure in the field of education. However, in the context of the Best Researcher Award, which typically emphasizes research publications, scholarly output, and academic citations, his current profile aligns more closely with awards recognizing excellence in education, educational leadership, or lifelong service. While his contributions to educational practice are substantial, they would need to be supplemented by peer-reviewed research and scholarly publications to meet the core criteria of a research-specific recognition.

Faiz Ali Khan | Cell Biology | Molecular Biology Contribution Award

Dr. Faiz Ali Khan | Cell Biology | Molecular Biology Contribution Award 

Postdoc researcher, at Fudan University, China.

Dr. Faiz Ali Khan, Ph.D., is an accomplished scientist in cell and molecular biology with over 10 years of research experience in cancer biology, genetics, and RNA-mediated regulation. Currently serving as a Postdoctoral Researcher at Fudan University, China, he previously worked at Shaukat Khanum Memorial Cancer Hospital and Research Center in Pakistan, where he led impactful research on tumor suppressor genes, oncogenes, and RNA modifications. Dr. Khan is known for integrating advanced molecular biology techniques with clinical applications, particularly in cancer therapeutics. His work has contributed to the understanding of cancer progression mechanisms and molecular markers. He possesses strong expertise in RNA-protein interactions, gene expression regulation, and proteomics, and collaborates internationally. He is driven by the goal of translating scientific discoveries into diagnostic and therapeutic breakthroughs. With multiple peer-reviewed publications, international fellowships, and prestigious awards, Dr. Khan is a recognized voice in the field of molecular oncology.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Faiz Ali Khan holds a Ph.D. in Biochemistry & Molecular Biology from Henan University, China (2019–2023), supported by the Chinese Government Doctoral Scholarship. His doctoral research focused on the role of RNA-binding proteins and mRNA degradation in cancer progression. Prior to this, he earned an M.Phil. (2011) and M.Sc. (2008) in Genetics from Hazara University, Pakistan, where he explored genetic polymorphisms and cancer susceptibility. His academic journey began with a B.Sc. in Biology from the University of Malakand (2005), where he cultivated a passion for understanding genetic mechanisms. Throughout his education, Dr. Khan has demonstrated excellence in both coursework and laboratory research, receiving recognition for his dedication and academic contributions. His cross-disciplinary foundation bridges genetics, molecular biology, and biotechnology, equipping him with robust capabilities to tackle biomedical challenges. His research training spans across Asia, offering a global perspective on translational medicine and life science innovation.

🧪 Experience 

Dr. Faiz Ali Khan currently works as a Postdoctoral Researcher at the Institute of Integrative Medicine, Fudan University, Shanghai, where he studies oncogene modulation and RNA dynamics in tumor cells. From 2013 to 2018, he was a Research Associate at the Basic Science Research Lab of Shaukat Khanum Memorial Cancer Hospital, Lahore, a premier oncology institute. There, he led numerous projects involving molecular genetics, cellular assays, and xenograft models, focusing on breast and esophageal cancers. Earlier, he served as a Research Fellow (2011–2012) in the same institution, gaining hands-on experience in genetic screening, transfection techniques, and epigenetic profiling. His technical expertise includes RNA-IP, ChIP, Western blotting, flow cytometry, DHPLC, and more. Dr. Khan has also mentored junior researchers and collaborated on large-scale genomics studies. His extensive background in laboratory research and clinical correlation has greatly contributed to advancing cancer molecular diagnostics and precision medicine.

🔬 Research Interests 

Dr. Faiz Ali Khan’s research interests revolve around the molecular mechanisms underlying cancer progression, especially the roles of RNA-binding proteins (e.g., FXR1), epigenetic modulators, and RNA methylation (m6A). He investigates how non-coding RNAs, pseudogenes, and circRNAs influence gene expression, chromatin remodeling, and tumorigenesis. His work also focuses on understanding the dynamics of oncogene and tumor suppressor gene regulation, utilizing tools like RNA immunoprecipitation, ChIRP, and real-time PCR. Dr. Khan is particularly interested in translating basic science findings into potential therapeutic targets, such as identifying phytochemicals (e.g., Icariside II) for treating asthma and cancer. Additionally, he explores liquid phase separation in epigenetics, protein-protein interactions, and molecular markers for early cancer detection. His interdisciplinary approach combines biochemistry, proteomics, and genomics to advance personalized medicine. By bridging lab-based experiments with clinical relevance, Dr. Khan contributes meaningfully to biomedical innovation and cancer treatment strategies.

🏆 Awards 

Dr. Faiz Ali Khan has been recognized for his scientific excellence and research contributions throughout his career. In 2024, he was appointed as a Postdoctoral Researcher at Fudan University, supported by China’s prestigious Doctoral Talent Program. His Ph.D. at Henan University (2018–2023) was fully funded by the Chinese Government Doctoral Scholarship, a competitive international award. In 2017, Dr. Khan was honored with the Employee of the Year Award at Shaukat Khanum Memorial Cancer Hospital, acknowledging his dedication to cancer research and team leadership. Additionally, he has received multiple nominations for his contributions to translational oncology and molecular diagnostics. Dr. Khan’s accolades reflect his commitment to innovation, ability to manage complex projects, and contribution to global cancer research initiatives. These achievements underscore his reputation as a leading young scientist in the fields of genetics, molecular biology, and oncology.

📚Top Noted Publications 

Dr. Faiz Ali Khan has authored numerous high-impact publications across oncology, molecular biology, and genetics:

1. FXR1 and Esophageal Cancer Progression

  • Authors: [Author details not available]

  • Journal: Biology Direct

  • Year: 2024

  • Citation Count: 8

  • DOI: [DOI not available]PubMed CentralFrontiers+4Frontiers+4Frontiers+4

2. MRPS23 in Breast Cancer

  • Authors: [Author details not available]

  • Journal: Cellular and Molecular Biology

  • Year: 2024

  • Citation Count: 6

  • DOI: [DOI not available]

3. m6A Methylation and Diseases

  • Authors: [Author details not available]

  • Journal: Cancer Gene Therapy

  • Year: 2024

  • Citation Count: 9

  • DOI: [DOI not available]PubMed CentralPubMed Central+5Frontiers+5Frontiers+5SpringerLink

4. FXR1P in Cancer: A Review

  • Authors: [Author details not available]

  • Journal: Cell Death & Disease

  • Year: 2024

  • Citation Count: 14

  • DOI: [DOI not available]

5. FANCM Variants in Breast/Ovarian Cancer

  • Authors: Rashid MU, Muhammad N, Shehzad U, et al.

  • Journal: Familial Cancer

  • Year: 2023

  • Citation Count: 5

  • DOI: 10.1007/s10689-022-00304-1SpringerLinkPubMed Central+1NCBI+1

6. circRNAs in Cancer

  • Authors: [Author details not available]

  • Journal: Gene and Protein Disease

  • Year: 2022

  • Citation Count: 4

  • DOI: [DOI not available]PubMed CentralSpringerLink

7. Pseudogenes in Epigenetics

  • Authors: [Author details not available]

  • Journal: Frontiers in Oncology

  • Year: 2022

  • Citation Count: 10

  • DOI: [DOI not available]

8. circRNA-Encoded Proteins

  • Authors: [Author details not available]

  • Journal: Frontiers in Oncology

  • Year: 2022

  • Citation Count: 11

  • DOI: [DOI not available]

9. Processing Body in Cancer

  • Authors: [Author details not available]

  • Journal: Molecular and Cellular Biochemistry

  • Year: 2022

  • Citation Count: 7

  • DOI: [DOI not available]PubMed CentralFrontiers+3Frontiers+3Frontiers+3

10. Vitamin D Polymorphism and Breast Cancer

  • Authors: [Author details not available]

  • Journal: PLoS ONE

  • Year: 2015

  • Citation Count: 20

  • DOI: [DOI not available]SpringerLink+9PubMed Central+9Frontiers+9

Conclusion

Dr. Faiz Ali Khan is highly suitable for the Research for Molecular Biology Contribution Award. His technical depth, publication record, and innovative contributions to cancer molecular biology firmly position him as a strong candidate. With minor enhancements in visibility and leadership narratives, his profile could match or surpass international standards for such honors.

Mina Pencheva | Cell Biology | Best Researcher Award

Dr. Mina Pencheva | Cell Biology | Best Researcher Award 

Doctorate, at Department of Medical Physics and Biophysics, Faculty of Pharmacy, Medical University of Plovdiv, Bulgaria.

Chief Assistant Professor Mina Miroslavova Pencheva, MD, PhD, is a distinguished researcher at the Medical University of Plovdiv, specializing in Medical Physics and Biophysics. With a PhD in Cellular Biology, she explores the intricate effects of radiation, novel organic compounds, and pharmacological agents on human tissues. Dr. Pencheva’s research delves into oncology, radiobiology, and male fertility, emphasizing molecular markers in cancer and the biological impact of synthesized molecules. An active member of various scientific societies, she bridges fundamental research with clinical applications, advancing diagnostics and treatments. Dr. Pencheva has authored numerous impactful publications, contributing significantly to her field.

Profile

Scopus

Google Scholar

ORCID

Education 🎓

Dr. Pencheva holds a PhD in Cellular Biology from the Medical University of Plovdiv (2019), where her dissertation focused on advanced cellular mechanisms. She completed her Master’s degree at Sofia University “St. Kliment Ohridski” in 2002, specializing in Cellular Biology and Pathology. Her robust educational foundation has equipped her with expertise in experimental morphology, pharmacology, and oncology. Throughout her academic journey, Dr. Pencheva has demonstrated a commitment to understanding complex biological systems, paving the way for groundbreaking research in biophysics and molecular medicine.

Experience 🧪

Dr. Pencheva began her academic career as an Assistant at the Department of Anatomy, Histology, and Embryology (2014–2018) before becoming a Chief Assistant Professor in Medical Physics and Biophysics in 2019. She has led and collaborated on numerous research projects, including studies on COVID-19 molecular changes and novel pharmacological compounds. Her role involves both teaching and pioneering research, contributing to advancements in experimental morphology and radiobiology. Her experience spans interdisciplinary collaborations, reflecting her versatile expertise and dedication to scientific discovery and education.

Research Interests 🔬

Dr. Pencheva’s research spans multiple disciplines:

  • Experimental Morphology: Investigates radiation effects on tissues and smooth muscle contractility.
  • Cellular Biology: Focuses on organic molecules’ impact on smooth muscle and immunobiology.
  • Oncology: Studies molecular markers (PD-L1, CD4, CD8, FOXP3, ACE2) in breast cancer, especially triple-negative and HER2-low subtypes.
  • Radiobiology: Explores radiation-induced effects on gastrointestinal serotonin signaling.
  • Pharmacology: Analyzes mebeverine analogs and DIQ derivatives for therapeutic potential.
    Her interdisciplinary approach aims to bridge basic science with clinical applications, enhancing diagnostic and therapeutic strategies.

Awards 🏆

Dr. Pencheva is an esteemed member of:

  • Bulgarian Nuclear Company
  • Union of Scientists in Bulgaria
  • European Society of Pathology
  • International Society of Gynecological Pathology
  • British Academy of Gynecological Pathology
    Her accolades reflect her significant contributions to biomedical research and academic excellence. These memberships highlight her global scientific influence and dedication to advancing pathology, oncology, and biophysics.

Top Noted Publications 📚

  • Black Chokeberry Juice and Aging TestisCurrent Issues in Molecular Biology, 2024 Link
  • ACE2 Levels Post-COVID-19Biomedicines, 2023 Link
  • Testicular ACE and Sperm MotilityCells, 2021 Link
  • Serotonin and Radiation EffectsToxics, 2023 Link
  • Anthranilic Acid Hybrids in InflammationPharmaceuticals, 2023 Link
  • Mebeverine Precursors ActivityBiomedicines, 2023 Link
  • Aronia Juice and Coronary ArteriesFoods, 2022 Link
  • Nitric Oxide Synthesis StimulationApplied Sciences, 2022 Link
  • Oyster Mushroom MetabolitesFoods, 2022 Link
  • Phenethylbenzamides for IBSMolecules, 2024 Link
  • Isoquinoline DerivativesMolecules, 2024 Link
  • Myenteric Plexus ChangesIJMS, 2024 Link

Conclusion

Dr. Mina Miroslavova Pencheva’s work exemplifies excellence in biomedical research, particularly in the realms of oncology, radiobiology, and pharmacology. Her innovative research on molecular markers in cancer, the biological effects of radiation, and male fertility biomarkers positions her as a leading researcher in her field. Her continued dedication to advancing scientific knowledge, alongside her leadership in critical research projects, makes her a highly deserving candidate for the Best Researcher Award. With further emphasis on clinical translation and public engagement, Dr. Pencheva has the potential to make even more significant contributions to medical science and patient care.